Targeting Renal Purinergic Signaling for the Treatment of Lithium-induced NDI

靶向肾脏嘌呤信号传导治疗锂诱导的 NDI

• 批准号: 8397534
• 负责人: BELLAMKONDA K KISHORE
• 金额: --
• 依托单位: VA SALT LAKE CITY HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8397534
• 关键词: Acute; Adverse effects; Affect; Agonist; Amiloride; Anxiety; Applications Grants; Argipressin; Biological; Biological Models; Bipolar Disorder; Blood; Cardiovascular system; Cell Culture Techniques; Cells; Chemosensitization; Chronic; Clinical; Clinical Trials; Coagulation Process; Combined Modality Therapy; Conscious; Culture Media; Data; Dehydration; Development; Drug Targeting; Duct (organ) structure; Elderly; Electrolytes; Equilibrium; Evaluation; Event; Formularies; Freedom; Functional disorder; Funding; Future; General Population; Genetic; Goals; Healthcare; Hypernatremia; Hypovolemia; Infusion procedures; Injection of therapeutic agent; Intervention; Intoxication; Investigation; Iraq; Kidney; Knock-out; Knockout Mice; Knowledge; Laboratories; Life; Liquid substance; Lithium; Major Depressive Disorder; Marines; Marketing; Mediating; Mental Depression; Methods; Mission; Modality; Modeling; Molecular; Morbidity - disease rate; Mus; Nature; Nephrogenic Diabetes Insipidus; Nucleotides; Outcome; P2Y2 receptor; PTGS2 gene; Pathway interactions; Patients; Pharmaceutical Preparations; Physiological; Plavix; Play; Post-Traumatic Stress Disorders; Prevalence; Purinoceptor; Rattus; Receptor Gene; Replacement Therapy; Reporting; Research; Resistance; Risk; Role; Safety; Signal Transduction; Soldier; Staging; Substance abuse problem; Surveys; System; Techniques; Therapeutic; Therapeutic Agents; Therapeutic Uses; Tissue Sample; Tissues; Urine; V2 Receptors; Vasopressins; Veterans; Vietnam; War; Water; Wild Type Mouse; Work; abstracting; analog; base; clinical practice; clinically relevant; clopidogrel; design; extracellular; feeding; hemodynamics; high risk; improved; in vivo; infancy; inhibitor/antagonist; innovation; insight; meetings; mortality; novel; older patient; operation; prevent; public health relevance; purinoceptor P2Y4; receptor; research study; response; screening; social; success; suicidal risk; urinary

DESCRIPTION (provided by applicant): 6. Project Summary/Abstract Nephrogenic diabetes insipidus (NDI) due to lithium therapy for bipolar disorder is one of the major nephrological problems among Veterans. NDI is a debilitating condition with an elevated risk of morbidity and even mortality, especially in elderly Veterans. Currently used therapeutic modalities for NDI are encountered with varying degrees of success as well as side effects, including lithium intoxication. Refinement and/or replacement of the current side effect-prone therapies with new drugs based on an improved understanding of molecular pathophysiology of lithium-induced NDI should result in improved efficacy and fewer side effects. Research carried out by us during the current funding period provided significant insights into the potential role of purinergic signaling in the genesis of lithium-induced NDI. These are: (i) purinergic signaling may play a potential overarching role in balancing the effect of arginine vasopressin (AVP) on the urinary concentration mechanism; (ii) in lithium-induced NDI, purinergic signaling in the medullary collecting duct is sensitized and involves more than one subtype of P2Y receptors; and (iii) P2Y2 receptor gene knockout mice are significantly resistant to the development of lithium-induced NDI, suggesting the potential role of purinergic signaling in the genesis of lithium-induced NDI. Based on our novel and significant observations we hypothesize that a deeper understanding of the role of renal purinergic signaling in Li-induced NDI offers better therapeutic modalities. A new class of drugs that target purinergic signaling may improve the safety and/or efficacy of the current medications in combination therapies, or replace them in the treatment of Li-induced NDI. The specific objective of the project are: 1) to investigate the role of purinergic signaling in the development of Li-induced AVP resistance using P2Y2 receptor knockout and wild type mice; 2) to investigate the role of purinergic signaling in Li-induced AVP resistance of medullary collecting duct using primary cultures of mouse inner medullary collecting duct cells; and 3) to investigate the effect of amiloride and COX-2 inhibition on Li-induced NDI in a background of blunted purinergic signaling. To achieve our objectives we will use P2Y2 receptor knockout mice, rats and cell culture models, and employ molecular, functional, immunohistochemical and cell signaling techniques.

描述（由申请人提供）： 6.项目摘要/摘要双相情感障碍锂治疗引起的肾源性尿崩症（NDI）是退伍军人的主要肾脏问题之一。NDI是一种使人衰弱的疾病，发病率甚至死亡率的风险升高，特别是在老年退伍军人中。目前使用的NDI治疗方式遇到了不同程度的成功以及副作用，包括锂中毒。基于对锂诱导的NDI的分子病理生理学的更好理解，用新药改进和/或替代目前的副作用倾向性疗法应导致改善的疗效和更少的副作用。我们在当前资助期间进行的研究为嘌呤能信号在锂诱导的NDI发生中的潜在作用提供了重要见解。这些措施包括：（i）嘌呤能信号可能在平衡精氨酸加压素（AVP）对尿浓缩机制的作用中发挥潜在的支配性作用;（ii）在锂诱导的NDI中，髓质集合管中的嘌呤能信号被敏化，并涉及一种以上的P2 Y受体亚型;和（iii）P2 Y2受体基因敲除小鼠对锂诱导的NDI的发展具有显著抗性，提示嘌呤能信号传导在锂诱导的NDI的发生中的潜在作用。基于我们的新的和重要的观察，我们假设，更深入地了解肾脏嘌呤能信号在锂诱导的NDI的作用提供了更好的治疗方式。靶向嘌呤能信号传导的一类新药物可能会提高目前药物在联合治疗中的安全性和/或有效性，或在锂诱导的NDI治疗中取代它们。本研究的具体目的是：1）利用P2 Y2受体敲除小鼠和野生型小鼠研究嘌呤能信号在锂诱导的AVP抗性发展中的作用; 2）利用原代培养的小鼠内髓集合管细胞研究嘌呤能信号在锂诱导的髓集合管AVP抗性中的作用;在嘌呤能信号减弱的背景下，研究阿米洛利和考克斯-2抑制剂对锂诱导的NDI的影响。为了实现我们的目标，我们将使用P2 Y2受体敲除小鼠，大鼠和细胞培养模型，并采用分子，功能，免疫组织化学和细胞信号转导技术。